The Role of Natriuretic Peptides (BNP and NT-proBNP) in Heart Failure
Katherine Soreng, PhD, Director, Clinical and Scientific Liaisons, Siemens Healthcare Diagnostics | 22.04.2015
The World Health Organization reports that cardiovascular disease is the number one cause of death in the industrialized world. Of the deaths attributed to CVD, an estimated 7.3 million were due to coronary heart disease, with another 6.2 million deaths caused by stroke. Heart failure care constitutes an increasing economic burden on the health care systems around the globe. While the lifetime costs of care of heart failure may vary in different regions of the world, there is no question that the high costs associated with heart failure significantly impact healthcare systems and economies. Natriuretic peptides (NPs) are a useful test to distinguish patients with heart failure from those without heart failure.
- Understand the pathophysiology and diagnosis of heart failure
- Learn about the clinical equivalence of using either BNP or NT-proBNP
- Understand how to use NPs with co-morbidities such as kidney disease and obesity
Webinars are complimentary and remain available online for 12 months after the live webinar date. Log on and learn!
For additional information on BNP, visit www.siemens.com/bnp.